Published in PLoS One on June 08, 2016
Cost-effectiveness analysis study of HPV testing as a primary cervical cancer screening in Thailand. Gynecol Oncol Rep (2017) 0.75
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst (1995) 18.86
Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med (2007) 9.53
The cervical cancer epidemic that screening has prevented in the UK. Lancet (2004) 7.72
Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet (1987) 6.91
Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med (2005) 6.72
Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA (2001) 5.96
Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer (2006) 5.87
The rising burden of cancer in the developing world. Ann Oncol (2006) 3.32
Benefits and costs of using HPV testing to screen for cervical cancer. JAMA (2002) 2.67
Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol (1998) 2.37
Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer (1991) 2.18
Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med (2011) 2.15
Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol (2000) 2.00
Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer (2004) 1.88
Chapter 7: Achievements and limitations of cervical cytology screening. Vaccine (2006) 1.86
European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document. Ann Oncol (2010) 1.86
Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol (2015) 1.84
Frequency of cervical smear abnormalities within 3 years of normal cytology. Obstet Gynecol (2000) 1.82
Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol (2006) 1.77
Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. J Natl Cancer Inst (2002) 1.71
The acceptability of self-collected samples for HPV testing vs. the pap test as alternatives in cervical cancer screening. J Womens Health Gend Based Med (2002) 1.70
HPV vaccination--more answers, more questions. N Engl J Med (2007) 1.64
Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst (2005) 1.31
Cervical cancer screening policies and coverage in Europe. Eur J Cancer (2009) 1.23
HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer (2007) 1.15
Cancer in developing countries. CA Cancer J Clin (1994) 1.14
The role of costs in comparative effectiveness research. Health Aff (Millwood) (2010) 1.12
Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. Int J Cancer (2010) 1.11
A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions. Br J Cancer (2000) 1.08
Comparison of the Abbott RealTime High-Risk Human Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA. J Clin Microbiol (2012) 1.05
The health and economic effects of HPV DNA screening in The Netherlands. Int J Cancer (2010) 1.05
History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results. J Clin Virol (2009) 1.04
Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br J Cancer (2012) 1.02
Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. Gynecol Oncol (2008) 0.98
Human papillomavirus infection in women with and without cervical cancer in Tehran, Iran. Int J Cancer (2011) 0.95
Epidemiology of cervical cancer and human papilloma virus infection among Iranian women - analyses of national data and systematic review of the literature. Gynecol Oncol (2012) 0.94
Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany. GMS Health Technol Assess (2010) 0.90
Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia. Salud Publica Mex (2008) 0.90
Cancer of the cervix: Early detection and cost-effective solutions. Int J Gynaecol Obstet (2015) 0.89
Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and cost-effectiveness. Obstet Gynecol (2010) 0.89
Cost-effectiveness of primary HPV screening for cervical cancer in Germany--a decision analysis. Eur J Cancer (2011) 0.87
Outcome of cervical cancer in Iranian patients according to tumor histology, stage of disease and therapy. Asian Pac J Cancer Prev (2010) 0.85
Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial. J Natl Cancer Inst (2015) 0.83
Comparison between visual inspection of cervix and cytology based screening procedures in Bangladesh. Asian Pac J Cancer Prev (2013) 0.82
A systematic review of economic aspects of cervical cancer screening strategies worldwide: discrepancy between economic analysis and policymaking. Asian Pac J Cancer Prev (2014) 0.82
Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis. BMC Med (2009) 0.81
Role of VIA in cervical cancer screening in low-resource countries. Mymensingh Med J (2011) 0.80
Management of precancerous cervical lesions in iran: a cost minimizing study. Asian Pac J Cancer Prev (2014) 0.79
Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system. Br J Cancer (2010) 0.79
Priority Setting for Improvement of Cervical Cancer Prevention in Iran. Int J Health Policy Manag (2015) 0.76